TAKASHI IKEDA

Chief

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Takashi Ikeda is a Chief at Shizuoka Cancer Center in Japan. His research primarily focuses on hematopoietic cell transplantation (HCT) outcomes, with recent studies examining the effects of donor characteristics on transplantation results, as well as optimizing graft-versus-host disease prophylaxis protocols. Additionally, he has contributed to understanding the impact of cytomegalovirus reactivation and other factors on patient survival in multiple myeloma and myelodysplastic syndromes.

Articles (7)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Collaborators (2)

Tatsuya Konishi

Ehime University Graduate School of Medicine

JAPAN

View details

Junya Kanda

講師 / Senior Lecturer/ Junior Associate Professor

Kyoto University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

TAKASHI IKEDA

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Comparison of methotrexate dosing protocols for graft-versus-host disease prophylaxis after unrelated hematopoietic stem cell transplantation

Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT

Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients With Myelodysplastic Syndrome: A Nationwide Retrospective Study From Adult Myelodysplastic Syndrome Working Group of the JSTCT

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis

Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies

Collaborators (2)

Tatsuya Konishi

Junya Kanda

Make your next move.